MedinCell is a French biopharmaceutical company specializing in long-acting injectable drug delivery. Its proprietary BEPO technology forms a biodegradable depot under the skin or in tissue that releases active ingredients over weeks or months from a single administration. Partners and programs target chronic and adherence-sensitive treatments, aiming to simplify dosing versus daily oral regimens.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2023 | 9.9 | — | -32 | — |
| 2024 | 9.2 | -7.9% | -25 | — |
| 2025 | 25.5 | 178.8% | -18.4 | — |
| 2026 | 19.5 | -23.6% | -31.3 | — |
All markets — KeepWinning global stock screener
Other companies on Euronext Paris: TotalEnergies EP Gabon Société Anonyme (EC), Mersen S.A. (MRN), Fnac Darty SA (FNAC), North Atlantic Energies (NAE), L'Oréal S.A. (OR), LVMH Moët Hennessy - Louis Vuitton, Société Européenne (MC)